Premium
Waiting List Treatment of Hepatocellular Carcinoma: When Do We Need Level 1 Evidence?
Author(s) -
Schwartz M.,
Lopez P.
Publication year - 2006
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2006.01572.x
Subject(s) - medicine , hepatocellular carcinoma , liver transplantation , milan criteria , carcinoma , randomized controlled trial , transplantation , general surgery , surgery
The impact of transarterial chemoembolization on patients with hepatocellular carcinoma awaiting liver transplantation could be on survival, waiting list drop out, complications, or increasing transplantability, but better evidence addressing all of these issues is needed. See also article by Lesurtel et al in this issue on page 2644.